Researchers linked to the Baby KJ personalized CRISPR case and Jennifer Doudna launched Aurora Therapeutics with seed backing to develop grouped, mutation‑targeted gene‑editing therapies. Menlo Ventures provided initial capital; Aurora’s leadership said the company will pursue an FDA 'plausible mechanism' regulatory pathway that could permit modular approvals for personalized edits covering multiple mutations within a disease. Aurora’s first clinical focus is phenylketonuria (PKU), aiming to address multiple patient mutations under a single development program. The founders argue that regulatory flexibility plus advances in design and manufacturing now make repeatable personalized editing commercially tractable.